UK | CGRP Education & Research Forum

Latest:

Atogepant open label data support long term efficacy and safety Sustained response to eptinezumab over 18 months Fresh insights on CGRP mAb and gepant prescribing New data support central action for fremanezumab and ubrogepant Zavegepant reduces need for analgesics AHS recommends anti-CGRP therapies as first line for migraine prevention Imaging data support central effects of erenumab Additive effects of multiple anti-CGRP therapies seen on CGRP-induced vasorelaxation

Erenumab benefits in refractory chronic migraine

Erenumab may be an effective and well tolerated therapy for patients with medically refractory, chronic migraine with and without medication overuse, according to results of a prospective single centre real world audit of patients treated for six months. The 162 patients in the audit had failed a mean of 8.4 preventive treatments at baseline, and …

Educational Partners and Supporters

This program is funded in part via an independent educational grant from AbbVie

Editorial PolicyCGRP Forum is an expert resource for clinicians and healthcare professionals working with migraine patients. All patients should discuss their medication with their healthcare professional. Unless otherwise indicated, opinions expressed in the CGRP Education and Research Forum are those of the contributors. Although every effort is made to ensure accuracy and avoid mistakes, no liability on the part of the CGRP Forum, the editors or the editorial board is accepted for the consequences of any misleading or inaccurate information.

UK

Erenumab benefits in refractory chronic migraine

Trials

Meeting Reports

Resources